Prognostic Model Based on Tumor Stemness Genes for Triple-negative Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 27

PMID 39730613

Authors

Min Ouyang

Yajun Gui

Namei Li

Lin Zhao

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive disease with a poor prognosis and lack of effective treatment. In this study, TNBCs were analyzed from the perspective of tumor stemness based on scRNA-seq data. The analysis showed that tumor cells of TNBC were divided into 4 subtypes, with subtype 2 having the highest stemness score. A prognostic model of 7 tumor stemness-related genes (AP2S1, CHML, FABP7, FADS2, PAXX, SDC1 and TOP2A) was developed based on marker genes of this subtype and TCGA data, and the predictive power of this feature was well validated in different clinical subgroups. TNBC patients in the low TS group had a better prognosis. In addition, drug sensitivity analysis showed that patients in the high TS (tumor stemness) score group were more sensitive to PD-L1 inhibitors and the chemotherapeutic agents. In conclusion, our study developed a prognostic model based on TNBC tumor stemness cell marker genes, which has a good ability to predict the prognosis of TNBC patients and the effect of response to drug therapy.

References

Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View

Dittmer J . Breast cancer stem cells: Features, key drivers and treatment options. Semin Cancer Biol. 2018; 53:59-74. DOI: 10.1016/j.semcancer.2018.07.007. View

Yeo S, Guan J . Breast Cancer: Multiple Subtypes within a Tumor?. Trends Cancer. 2017; 3(11):753-760. PMC: 5802368. DOI: 10.1016/j.trecan.2017.09.001. View

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

Fultang N, Chakraborty M, Peethambaran B . Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resist. 2022; 4(2):321-342. PMC: 9019272. DOI: 10.20517/cdr.2020.106. View

Yang Y, Tao X, Li C, Wang C . MicroRNA-494 acts as a tumor suppressor in pancreatic cancer, inhibiting epithelial-mesenchymal transition, migration and invasion by binding to SDC1. Int J Oncol. 2018; 53(3):1204-1214. DOI: 10.3892/ijo.2018.4445. View

Deepak K, Vempati R, Nagaraju G, Dasari V, S N, Rao D . Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020; 153:104683. DOI: 10.1016/j.phrs.2020.104683. View

Wang Y, Bi X, Luo Z, Wang H, Ismtula D, Guo C . Gelsolin: A comprehensive pan-cancer analysis of potential prognosis, diagnostic, and immune biomarkers. Front Genet. 2023; 14:1093163. PMC: 10076574. DOI: 10.3389/fgene.2023.1093163. View

Cristofanilli M, Turner N, Bondarenko I, Ro J, Im S, Masuda N . Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre,.... Lancet Oncol. 2016; 17(4):425-439. DOI: 10.1016/S1470-2045(15)00613-0. View

10.

Zhou J, Zhao J, Su C . Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression. Curr Cancer Drug Targets. 2021; 21(8):631-639. DOI: 10.2174/1568009619666210316112333. View

11.

Jiang J, Tang Q, Gong J, Jiang W, Chen Y, Zhou Q . Radiosensitizer EXO-miR-197-3p Inhibits Nasopharyngeal Carcinoma Progression and Radioresistance by Regulating the AKT/mTOR Axis and HSPA5-mediated Autophagy. Int J Biol Sci. 2022; 18(5):1878-1895. PMC: 8935226. DOI: 10.7150/ijbs.69934. View

12.

Bastiancich C, Bastiat G, Lagarce F . Gemcitabine and glioblastoma: challenges and current perspectives. Drug Discov Today. 2017; 23(2):416-423. DOI: 10.1016/j.drudis.2017.10.010. View

13.

Szebenyi K, Furedi A, Bajtai E, Sama S, Csiszar A, Gombos B . Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells. Drug Resist Updat. 2023; 71:101007. DOI: 10.1016/j.drup.2023.101007. View

14.

Baslan T, Hicks J . Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017; 17(9):557-569. DOI: 10.1038/nrc.2017.58. View

15.

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

16.

Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R . Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021; 40(3):282-293. PMC: 10476784. DOI: 10.1200/JCO.21.02554. View

17.

Park S, Choi J, Nam J . Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678244. DOI: 10.3390/cancers11070965. View

18.

Wang Y, Li Y, Jing Y, Yang Y, Wang H, Ismtula D . Tubulin alpha-1b chain was identified as a prognosis and immune biomarker in pan-cancer combing with experimental validation in breast cancer. Sci Rep. 2024; 14(1):8201. PMC: 11001892. DOI: 10.1038/s41598-024-58982-z. View

19.

Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y . Author Correction: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2018; 8(1):4276. PMC: 5840400. DOI: 10.1038/s41598-018-22220-0. View

20.

Heagerty P, Zheng Y . Survival model predictive accuracy and ROC curves. Biometrics. 2005; 61(1):92-105. DOI: 10.1111/j.0006-341X.2005.030814.x. View